Dickran Kazandjian, Md

This phase 2 trial tests whether adding linvoseltamab to standard lenalidomide maintenance can eliminate remaining cancer cells in people with multiple myeloma. About 32 participants will receive the combination for up to 24 cycles. The goal is to see if this approach can deepen …